GlassScriptPhysician profile
Jack Waxman
NPI 1104824994
$75,334.66
in general payments reported to CMS, 2019-2025
35 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $15K · 2021: $6,374 · 2022: $605 · 2023: $648 · 2024: $998 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Consulting Fee: $125 · Education: $47.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.16 |
| Consulting Fee | $125.00 |
| Education | $47.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31,439.79 | 2019-2025 | Evenity, Prolia, Tavneos |
| Novartis Pharmaceuticals Corporation | $24,098.60 | 2019-2021 | |
| Pfizer INC. | $5,158.99 | 2019-2024 | |
| Abbvie INC. | $3,268.32 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $3,143.56 | 2019-2021 | |
| Radius Health, INC. | $1,356.04 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $832.20 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $828.74 | 2019-2025 | Tremfya |
| Janssen Biotech, INC. | $661.91 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $542.11 | 2019-2021 | |
| Ucb, INC. | $526.41 | 2019-2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $449.62 | 2020-2021 | |
| Genzyme Corporation | $429.49 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $326.70 | 2020-2021 | |
| Celgene Corporation | $322.98 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $275.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.38 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $263.25 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $220.92 | 2019 | |
| Aurinia Pharma U.S., INC. | $176.42 | 2022-2024 | Lupkynis |
| Tersera Therapeutics LLC | $125.00 | 2025 | |
| Genentech USA, INC. | $105.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $102.44 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $75.62 | 2019-2021 | |
| Biogen, INC. | $45.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.11 | 2019 | |
| Allergan, INC. | $40.86 | 2020 | |
| Genentech, INC. | $38.77 | 2019 | |
| Medexus Pharma, INC. | $37.53 | 2019 | |
| Gilead Sciences, INC. | $33.56 | 2020 | |
| Daiichi Sankyo INC. | $29.61 | 2019 | |
| Melinta Therapeutics, LLC | $16.83 | 2019 | |
| Assertio Therapeutics, INC. | $16.11 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.18 | 2021 | |
| Zyla Life Sciences, INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Waxman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.